Finance
Q&A: Loncar dissects the intersection of cancer research and investment
Brad Loncar Much is changing in cancer research and scientific progress in diagnosis and treatment, which has led to a better outlook for cancer patients. Pharmaceutical companies with exposure to oncology have offered better earnings growth and high returns...











